MFN2 and Charcot-Marie-Tooth disease type 2A1: Indeed, Franco et al. (2016) designed minipeptides to manipulate the activity of Mfn2, and demonstrated that activation of Mfn2 could reverse mitochondrial defects associated with CMT2A cell models.